The Pharmacy of the World Has a Problem. Quantum Biology Might Fix It
India carries 20% of the world’s disease burden. 77 million diabetics. Over 1.4 million new cancer cases every year.
Let that sink in.
India is the pharmacy of the world. Third largest drug producer by volume. 20% global share in generic exports. Sun Pharma, Cipla, Dr. Reddy’s supply hospitals from Baltimore to Nairobi.
But here is the problem.
India contributes just 1.5% of pharmaceuticals by value. It manufactures the world’s medicines. It does not discover them. The gap between making a generic and owning the molecule is the difference between being a contractor and being the architect.
A new generation of companies is trying to change that. Starting at the quantum level.
AI transformed drug discovery but hits a ceiling at the actual physics of biology. Classical computers cannot simulate how a protein folds or whether a drug binds to its target. They approximate. In drug development, approximation costs billions.
Quantum chemistry does not approximate. It simulates molecular systems with physical accuracy. Quantum sensing detects biomarkers before symptoms appear. For a healthcare system that is chronically overwhelmed, that is not a luxury. That is load management.
The global quantum computing in healthcare market is projected to reach $4.1 billion by 2035. India’s curve is steeper: $482 million today, $3.8 billion by 2031.
The mission is live.
₹6,003 crore committed under the National Quantum Mission. ₹720 crore for quantum fabrication facilities at IIT Bombay and IISc Bengaluru. The NQM cohort has expanded to 17 startups. BIRAC received nearly 200 applications spanning cancer research, gene therapy, and bio-manufacturing.
This is not a government programme moving at government speed. It is ahead of its own timeline.
Indian founders are building the answer.
QpiAI has raised $39 million, co-led by Avataar Ventures and the NQM itself. Targeting ₹100 crore in revenue by 2026. “By 2030, we expect to cross $1 billion in revenue. Demand from pharma, defense, chemicals will explode.”
Quantum Biosciences is building quantum biosensors for early stage cancer detection at IISc Bengaluru. Mapping cellular stress signals to biomarkers before diagnosis becomes urgent.
India has patients. Millions of them. Quantum biosensors validated on Indian disease profiles will be export ready in a way no Western lab prototype can match.
The country that gave the world its generic drugs is now building the quantum tools to discover the next generation of them.
If you are a founder building at this intersection, reach out. I want to hear from you.
Table of Content
- 1. Why Advanced Manufacturing Is Having Its Moment in India
- 2. The Real Challenge: From Prototype to Production
- 3. Different Ways Founders Are Building in Advanced Manufacturing
- 4. Capital Reality: Why Hardware Is Harder (and Worth It)
- 5. Case Study Lens: What Good Looks Like
- 6. What Investors Look For (Beyond the Pitch Deck)
- 7. The Founder Reality: It Takes Time, But It Compounds
- 8. The Road Ahead: India’s Idea-to-Factory Moment
- 9. FAQs